News

InterMune to divest Actimmune for $55 million; to focus on Esbriet

22-05-2012

California, USA-based biotech firm InterMune (Nasdaq: ITMN) says that it has reached a definitive agreement…

ActimmuneBiotechnologyEsbrietFinancialImmunologicalsInterMuneMergers & AcquisitionsRespiratory and PulmonaryVidara Therapeutics

Dutch firm Pharming initiates DNage divestment, to focus on Rhucin

18-05-2010

Netherlands-based biotechnology company Pharming Group NV said yesterday that it has initiated the process…

BiotechnologyCardio-vascularDNageFinancialImmunologicalsMergers & AcquisitionsPharmaceuticalPharmingResearchRhucin

COMPANY SPOTLIGHT

Menarini

Back to top